GNMSF vs JNJ: Which Stock is Better?

Side-by-side comparison of Genmab A/S and Johnson & Johnson in 2026

Comparison Updated:

GNMSF

Genmab A/S

$330.37

JNJ

Johnson & Johnson

$218.21

Key Metrics Comparison

MetricGNMSFJNJWinner
Market Cap$20.35B$525.73BJNJ
P/E Ratio14.4721.10GNMSF
EPS (TTM)$22.83$10.34GNMSF
Revenue Growth0.2%0.1%GNMSF
Gross Margin94.4%68.4%GNMSF

Analyze GNMSF

Full quant analysis

Analyze JNJ

Full quant analysis

Analyze Each Stock

Frequently Asked Questions

Is GNMSF or JNJ a better investment?

Comparing GNMSF and JNJ: Genmab A/S has a market cap of $20.35B while Johnson & Johnson has $525.73B. Both companies have their strengths - use our detailed metrics comparison to make an informed decision.

What is the difference between GNMSF and JNJ?

GNMSF (Genmab A/S) and JNJ (Johnson & Johnson) differ in valuation, growth rates, and profitability metrics. Our comparison shows which company leads in each category.

Which stock has better value: GNMSF or JNJ?

Based on P/E ratios, GNMSF trades at a lower multiple (14.5x vs 21.1x).

Which is growing faster: GNMSF or JNJ?

GNMSF has higher revenue growth at 0.2% vs 0.1% for JNJ.

Which company is more profitable: GNMSF or JNJ?

Genmab A/S (GNMSF) has higher gross margins at 94.4% compared to 68.4% for JNJ.

Which is the larger company: GNMSF or JNJ?

Johnson & Johnson (JNJ) is larger with a market cap of $525.73B compared to $20.35B for GNMSF.

Should I buy GNMSF or JNJ in 2026?

Both GNMSF and JNJ have investment merit. GNMSF trades at $330.37 while JNJ trades at $218.21. Consider your investment goals, risk tolerance, and portfolio diversification before deciding. Our AI analysis tools can provide personalized insights.

What are the key differences between GNMSF and JNJ stock?

Key differences: Market Cap ($20.35B vs $525.73B), P/E Ratio (14.5x vs 21.1x), Revenue Growth (0.2% vs 0.1%), Gross Margin (94.4% vs 68.4%).

Popular Stock Comparisons